You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 9 No. 6, Nov-Dec 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oculoplastic Surgery
 •Trauma/ Maxillofacial Surgery
 •Radiation Therapy
 •Prognosis/ Outcomes
 •Otolaryngology/ Head & Neck Surgery
 •Alert me on articles by topic

Sparing the Eye in Craniofacial Surgery for Superior Nasal Vault Malignant Neoplasms

Analysis of Benefit

Garth F. Essig, MD; Steven A. Newman, MD; Paul A. Levine, MD

Arch Facial Plast Surg. 2007;9(6):406-411.

Objective  To evaluate orbital and ophthalmologic function following standardized eye-sparing protocol for treating superior nasal vault malignant neoplasms.

Design  A retrospective review of patients with sinonasal malignant neoplasms who underwent preoperative radiation therapy with or without chemotherapy and craniofacial resection (CFR) with eye preservation. Pretreatment and posttreatment ophthalmologic evaluations were performed.

Results  A total of 59 patients underwent eye-sparing therapy between 1983 and 2005; 36 had invasion of the lamina with or without periorbital resection (61%). The most common abnormality was esthesioneuroblastoma (37 cases; 63%), most of which were Kadish stage C (n = 26). The most common preoperative ophthalmologic findings were motility disturbances (18 cases; 31%), afferent pupillary dysfunction and change in acuity (17 cases; 29%), and proptosis (17 cases; 29%). A total of 36 patients were available for long-term follow-up (mean follow-up, 61 months); 35 of these retained functional vision (97%); and 1 patient had a nonfunctional eye.

Conclusions  Standardized treatment for superior nasal vault malignant neoplasms using an eye-sparing CFR remains a sound approach both oncologically and ophthalmologically. Most patients with advanced disease present with ophthalmologic findings, and most posttreatment eye findings are notable only on detailed examination and either resolve spontaneously in the acute-care setting or do not require surgical repair.


Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Drs Essig and Levine) and Ophthalmology (Dr Newman), University of Virginia Health System, Charlottesville.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Orbital and Ophthalmic Plastic Surgery Theme Issue
Goldberg
Arch Ophthalmol 2007;125:1708-1709.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.